EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

被引：14

作者：

Michels, Sebastian ^{[1
]}

Gardizi, Masyar ^{[1
]}

Schmalz, Petra ^{[2
]}

Thurat, Meike ^{[1
]}

Pereira, Eva ^{[3
]}

Sebastian, Martin ^{[4
]}

Carcereny, Enric ^{[5
]}

Corral, Jesus ^{[6
]}

Paz-Ares, Luis ^{[6
]}

Felip, Enriqueta ^{[7
]}

Grohe, Christian ^{[8
]}

Rodriguez Abreu, Delvys ^{[9
]}

Insa Molla, Amelia ^{[10
]}

Bischoff, Helge ^{[11
]}

Reck, Martin ^{[12
]}

Karachaliou, Niki ^{[13
,14
]}

Scheel, Andreas ^{[15
]}

Brandes, Vanessa ^{[1
]}

Rieke, Fischer ^{[1
]}

Nogova, Lucia ^{[1
]}

Scheffler, Matthias ^{[1
]}

Franklin, Jeremy ^{[16
]}

Hellmich, Martin ^{[16
]}

Massuti, Bartomeu ^{[17
]}

Buettner, Reinhard ^{[15
]}

Rosell, Rafael ^{[18
]}

Wolf, Juergen ^{[1
]}

机构：

[1] Univ Hosp Cologne, Lung Canc Grp Cologne, Cologne, Germany

[2] Clin Trial Ctr Cologne, Cologne, Germany

[3] Spanish Lung Canc Grp, Barcelona, Spain

[4] Univ Klin Frankfurt Main, Frankfurt, Germany

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol, Badalona, Spain

[6] Hosp Univ Virgen Del Rocio, Seville, Spain

[7] Vall DHebron Univ Hosp, Barcelona, Spain

[8] Evangel Lungenklin, Berlin, Germany

[9] Univ Hosp Maternoinfantil Canarias, Las Palmas Gran Canaria, Spain

[10] Univ Hosp Clin Valencia, Med Oncol, Valencia, Spain

[11] Thoraxklin Heidelberg, Heidelberg, Germany

[12] Lungclin Grosshansdorf, Grosshansdorf, Germany

[13] Hosp Sagrat Cor, Barcelona, Spain

[14] Germans Trias & Pujol Hlth Sci Inst & Hosp, Barcelona, Spain

[15] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[16] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany

[17] Alicante Univ Hosp, Med Oncol, Alicante, Spain

[18] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

NSCLC; crizotinib; ros1;

D O I：

10.1016/j.jtho.2016.11.428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.05

引用

页码：S379 / S380

页数：2

共 50 条

[41] Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases
Zheng, Jing
Zhou, Jian-Ya
Bao, Zhang
Shen, Qian
Cao, He
Zhou, Jian-Ying
CHINESE MEDICAL JOURNAL, 2020, 133 (14) : 1725 - 1726
[42] ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission
Blaukovitsch, Markus
Hofer, Johann
Hutarew, Georg
Muellauer, Leonhard
Ingrid, Simonitsch-Klupp
Studnicka, Michael
THORACIC CANCER, 2014, 5 (05) : 455 - 459
[43] Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
Wu, Y.
Lu, S.
Yang, J. C.
Zhou, J.
Seto, T.
Ahn, M.
Su, W.
Yamamoto, N.
Kim, D.
Paolini, J.
Usari, T.
Wilner, K.
Goto, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1087 - S1087
[44] Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence
Nadal, Ernest
Rifi, Nada
Kane, Sarah
Mbacke, Sokhna
Starkman, Lindsey
Suero, Beatrice
Le, Hannah
Samjoo, Imtiaz A.
LUNG CANCER, 2024, 192
[45] Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report
Zhang, Yi
Yu, Min
Yuan, Mingming
Chen, Rongrong
Huang, Mei-Juan
CLINICAL LUNG CANCER, 2020, 21 (02) : E78 - E83
[46] Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
Wei, Shuli
Hu, Mangsha
Yang, Yan
Huang, Xiaojie
Li, Baizhou
Ding, Liren
Wang, Pingli
FRONTIERS IN ONCOLOGY, 2022, 12
[47] Efficacy of of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
Chen, Yen-Fu
Hsieh, Min-Shu
Wu, Shang-Gin
Chang, Yih-Leong
Yu, Chong-Jen
Yang, James Chih-Hsin
Yang, Pan-Chyr
Shih, Jin-Yuan
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 1140 - 1152
[48] Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants
Xu, Haiyan
Zhang, Quan
Liang, Li
Li, Junling
Liu, Zhefeng
Li, Weihua
Yang, Lu
Yang, Guangjian
Xu, Fei
Ying, Jianming
Zhang, Shucai
Wang, Yan
CANCER MEDICINE, 2020, 9 (10): : 3328 - 3336
[49] Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
Shimokawa, Mototsugu
Nosaki, Kaname
Seto, Takashi
Ohashi, Kadoaki
Morise, Masahiro
Horinouchi, Hidehito
Sakakibara, Jun
Murakami, Haruyasu
Yano, Seiji
Satouchi, Miyako
Matsumoto, Shingo
Goto, Koichi
Yoh, Kiyotaka
TRIALS, 2020, 21 (01)
[50] Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
Mototsugu Shimokawa
Kaname Nosaki
Takashi Seto
Kadoaki Ohashi
Masahiro Morise
Hidehito Horinouchi
Jun Sakakibara
Haruyasu Murakami
Seiji Yano
Miyako Satouchi
Shingo Matsumoto
Koichi Goto
Kiyotaka Yoh
Trials, 21

← 1 2 3 4 5 →